https://respirerx.com/cortex-pharmaceuticals-inc-announces-name-change-and-symbol-ch/2021-09-03T17:31:45-04:00https://respirerx.com/cortex-pharmaceuticals-inc-to-present-at-the-14th-annual-bio-investor-forum/2021-09-03T17:32:13-04:00https://respirerx.com/cortex-slide-deck-presentation-at-the-14th-annual-bio-investor-forum/2021-09-03T17:31:56-04:00https://respirerx.com/respirerx-pharmaceuticals-inc-to-present-at-the-jefferies-2016-healthcare-conference/2021-09-03T17:28:22-04:00https://respirerx.com/respirerx-pharmaceuticals-inc-files-march-31-2016-quarterly-report-on-form-10-q/2021-09-03T17:28:27-04:00https://respirerx.com/respirerx-pharmaceuticals-inc-the-university-of-alberta-and-the-university-of-florida-provide-update-on-collaborative-research-activities/2021-09-03T17:28:32-04:00https://respirerx.com/respirerx-pharmaceuticals-inc-files-december-31-2015-annual-report-on-form-10-k/2021-09-03T17:28:36-04:00https://respirerx.com/respirerx-pharmaceuticals-inc-to-present-at-the-28th-annual-roth-conference-on-march-15-2016/2021-09-03T17:28:41-04:00https://respirerx.com/respirerx-pharmaceuticals-inc-announces-removal-of-fda-clinical-hold-on-cx1739-and-initiation-of-phase-2a-clinical-trial-by-march-31-2016/2021-09-03T17:31:25-04:00https://respirerx.com/respirerx-pharmaceuticals-inc-to-present-at-18th-annual-bio-ceo-investor-conference/2021-09-03T17:31:29-04:00https://respirerx.com/respirerx-pharmaceuticals-inc-announces-new-research-program-with-the-national-institute-of-drug-abuse/2021-09-03T17:31:34-04:00https://respirerx.com/respirerx-pharmaceuticals-inc-to-present-at-noble-financial-capital-markets-twelfth-annual-investorequity-conference-noblecon12/2021-09-03T17:31:39-04:00https://respirerx.com/respirerx-pharmaceuticals-inc-to-present-at-8th-annual-biotech-showcase-2016/2021-09-03T17:31:50-04:00https://respirerx.com/cortex-pharmaceuticals-inc-to-present-at-rodman-renshaw-17th-annual-global-investment-conference/2021-09-03T17:32:20-04:00https://respirerx.com/cortex-pharmaceuticals-inc-announces-appointment-of-james-s-j-manuso-ph-d-as-president-and-chief-executive-officer-vice-chairman-of-the-board-of-directors/2021-09-03T17:32:28-04:00https://respirerx.com/cortex-pharmaceuticals-inc-enters-into-new-license-agreement-with-the-university-of-illinois-granting-cortex-patent-rights-to-the-use-of-cannabinoids-for-the-treatment-of-sleep-related-breathing-dis/2021-09-03T17:33:07-04:00https://respirerx.com/cortex-pharmaceuticals-inc-announces-appointment-of-two-directors-expands-board-to-five-members/2021-09-03T17:33:02-04:00https://respirerx.com/cortex-pharmaceuticals-inc-to-present-at-rodman-renshaw-16th-annual-global-investment-conference-on-wednesday-september-10-2014/2021-09-03T17:32:57-04:00https://respirerx.com/cortex-pharmaceuticals-inc-to-present-at-7th-annual-biotech-showcase-2015/2021-09-03T17:32:53-04:00https://respirerx.com/nybio-conference-presentation/2021-09-03T17:32:34-04:00https://respirerx.com/cortex-pharmaceuticals-inc-to-present-at-newyorkbio-25th-anniversary-conference/2021-09-03T17:32:38-04:00https://respirerx.com/cortex-pharmaceuticals-inc-files-december-31-2014-annual-report-on-form-10-k-provides-update-on-current-status-and-activities/2021-09-03T17:32:48-04:00https://respirerx.com/respirerx-pharmaceuticals-inc-to-present-at-the-cantor-fitzgerald-2nd-annual-healthcare-conference-on-july-13-2016/2021-09-03T17:28:16-04:00https://respirerx.com/respirerx-slide-deck-presentation-at-cantor-fitzgerald-healthcare-conference/2021-09-03T17:28:10-04:00https://respirerx.com/respirerx-pharmaceuticals-inc-files-june-30-2016-quarterly-report-on-form-10-q/2021-09-03T17:26:55-04:00https://respirerx.com/respirerx-pharmaceuticals-inc-announces-1-for-325-reverse-stock-split/2021-09-03T17:26:45-04:00https://respirerx.com/respirerx-pharmaceuticals-inc-to-present-at-the-rodman-renshaw-18th-annual-global-investment-conference-on-september-12-2016/2021-09-03T17:26:40-04:00https://respirerx.com/respirerx-pharmaceuticals-inc-announces-preliminary-top-line-analysis-of-data-from-duke-university-phase-2a-clinical-trial-of-cx1739/2021-09-03T17:26:35-04:00https://respirerx.com/respirerx-slide-deck-presentation-at-rodman-conference/2021-09-03T17:26:29-04:00https://respirerx.com/respirerx-pharmaceuticals-inc-retracts-efficacy-data-in-september-12-2016-press-release-announcing-preliminary-top-line-analysis-of-safety-and-efficacy-data-from-duke-university-phase-2a-clinicial/2021-09-03T17:26:24-04:00https://respirerx.com/respirerx-pharmaceuticals-inc-to-present-at-the-bio-investor-forum-on-tuesday-october-18-2016-at-the-st-francis-hotel-in-san-francisco-california/2021-09-03T17:26:15-04:00https://respirerx.com/bio-investor-forum-slide-deck/2021-09-03T17:26:19-04:00https://respirerx.com/respirerx-pharmaceuticals-inc-files-september-30-2016-quarterly-report-on-form-10-q/2021-09-03T17:26:11-04:00https://respirerx.com/respirerx-pharmaceuticals-inc-announces-data-for-cx1739-clinical-study-in-opioid-induced-respiratory-depression/2021-09-03T17:26:05-04:00https://respirerx.com/respirerx-pharmaceuticals-inc-announces-positive-results-from-phase-2b-pace-study-conducted-by-the-university-of-illinois-dronabinol-reduces-symptoms-of-obstructive-sleep-apnea/2021-09-03T17:26:01-04:00https://respirerx.com/respirerx-pharmaceuticals-inc-to-present-at-9th-annual-biotech-showcase-2017/2021-09-03T17:25:56-04:00https://respirerx.com/biotech-showcase-slide-deck/2021-09-03T17:25:51-04:00https://respirerx.com/respirerx-pharmaceuticals-inc-to-present-at-bio-ceo-investor-conference-2017/2021-09-03T17:25:47-04:00https://respirerx.com/bio-ceo-investor-slide-deck-presentation/2021-09-03T17:25:42-04:00https://respirerx.com/respirerx-pharmaceuticals-inc-announces-participation-sleep-2017-in-boston-ma/2021-09-03T17:25:36-04:00https://respirerx.com/sleep-2017-conference-poster/2021-09-03T17:25:29-04:00https://respirerx.com/respirerx-pharmaceuticals-inc-to-present-at-the-2017-marcum-microcap-conference/2021-09-03T17:25:26-04:00https://respirerx.com/061617-respirerx-presentation-at-2017-marcum-microcap-conference/2021-09-03T17:25:21-04:00https://respirerx.com/cannabinoid-platform/2017-07-11T23:10:16-04:00https://respirerx.com/ampakines-platform/2017-07-11T23:26:47-04:00https://respirerx.com/dronabinol-executive-summary/2017-07-11T23:28:55-04:00https://respirerx.com/ampakines-executive-summary/2017-07-11T23:30:16-04:00https://respirerx.com/1571-2/2017-08-24T10:37:39-04:00https://respirerx.com/respirerx-pharmaceuticals-inc-files-june-30-2017-quarterly-report-on-form-10-q-and-provides-update/2021-09-03T17:25:11-04:00https://respirerx.com/respirerx-pharmaceuticals-inc-to-present-at-2017-rodman-renshaw-conference/2021-09-03T17:25:06-04:00https://respirerx.com/091217-respirerx-presentation-at-2017-rodman-renshaw-conference/2021-09-03T17:25:00-04:00https://respirerx.com/respirerx-pharmaceuticals-announces-publication-of-2b-pace-study/2021-09-03T17:24:55-04:00https://respirerx.com/respirerx-announces-debt-forgiveness-for-past-due-cash-compensation/2021-09-03T17:24:49-04:00https://respirerx.com/respirerx-pharmaceuticals-publishes-scientific-evidence-demonstrating-cx717-neurobiological-safety/2021-09-03T17:24:44-04:00https://respirerx.com/respirerx-pharmaceuticals-inc-to-present-at-10th-annual-biotech-showcase-2018/2021-09-03T17:24:37-04:00https://respirerx.com/1658-2/2021-09-03T17:24:31-04:00https://respirerx.com/06-19-2018-respirerx-pharmaceuticals-inc-advancing-dronabinol-obstructive-sleep-apnea-program-with-letter-of-intent-for-co-development-and-supply-agreement-with-noramco-inc/2021-09-03T17:24:26-04:00https://respirerx.com/respirerx-pharmaceuticals-inc-announces-resignation-of-dr-james-s-manuso/2021-09-03T17:24:21-04:00https://respirerx.com/07-25-2018-rspi-announces-publication-of-ampakine-data/2021-09-03T17:24:13-04:00https://respirerx.com/09-10-18-respirerx-pharmaceuticals-inc-secures-clinical-and-commercial-supply-of-dronabinol-for-obstructive-sleep-apnea-with-the-signing-of-a-development-and-supply-agreement-with-noramco/2021-09-03T17:24:05-04:00https://respirerx.com/12-10-2018-respirerx-pharmaceuticals-inc-executives-presenting-at-the-international-cannabinoid-derived-pharmaceuticals-summit/2021-09-03T17:23:57-04:00https://respirerx.com/2-19-2019-respirerx-pharmaceuticals-inc-and-impression-healthcare-limited-announce-agreement-to-explore-commercialization-of-dronabinol-for-the-treatment-of-obstructive-sleep-apnea-in-austr/2021-09-03T17:23:41-04:00https://respirerx.com/1-3-2019-respirerx-pharmaceuticals-inc-appoints-james-sapirstein-as-executive-vice-chairman-of-the-board-of-directors/2021-09-03T17:23:50-04:00https://respirerx.com/7-30-2019-respirerx-pharmaceuticals-inc-send-notice-letter-to-the-board-of-directors-of-therapix-biosciences-ltd/2021-09-03T17:23:34-04:00https://respirerx.com/9-9-2019-respirerx-pharmaceuticals-inc-executives-participating-in-the-2nd-annual-international-cannabinoid-derived-pharmaceuticals-summit/2021-09-03T17:23:28-04:00https://respirerx.com/2-3-2020-respirerx-pharmaceuticals-inc-announces-appointment-of-tim-jones-to-its-board-of-directors/2020-02-02T22:45:58-05:00https://respirerx.com/2-5-2020-respirerx-pharmaceuticals-inc-announces-the-filing-of-broad-enabling-cannabinoid-continuation-in-part-and-new-provisional-patent-applications/2020-02-05T22:47:40-05:00https://respirerx.com/2-12-2020-respirerx-pharmaceuticals-inc-progress-and-status-report/2020-02-11T22:50:36-05:00https://respirerx.com/3-4-2020-respirerx-pharmaceuticals-inc-announces-entry-into-option-agreement-to-license-gabaa-receptor-allosteric-neuromodulator-intellectual-property-from-the-uwm-research-foundation-in/2020-03-05T13:11:49-05:00https://respirerx.com/05-06-2020-respirerx-pharmaceuticals-inc-announces-appointment-of-timothy-jones-as-president-and-chief-executive-officer/2020-05-06T11:43:41-04:00https://respirerx.com/08-03-2020-respirerx-pharmaceuticals-inc-announces-extension-to-long-term-employment-contract-with-tim-jones-as-president-and-chief-executive-officer/2020-08-03T21:35:37-04:00https://respirerx.com/08-04-2020-respirerx-pharmaceuticals-inc-announces-2-million-funding-commitment-allowing-option-exercise-with-uwm-research-foundation-inc-and-entry-into-a-license-agreement-for-gabaa-r/2020-08-04T12:54:54-04:00https://respirerx.com/08-04-2020-ceo-of-respirerx-pharmaceuticals-inc-tim-jones-is-featured-on-the-stock-day-podcast/2020-08-17T18:23:30-04:00https://respirerx.com/09-25-2020-respirerx-pharmaceuticals-inc-announces-appointment-of-david-dickason-as-senior-vice-president-pre-clinical-product-development/2020-09-25T10:15:38-04:00https://respirerx.com/10-06-2020-respirerx-pharmaceuticals-inc-announces-publication-of-preclinical-results-supporting-the-use-of-ampakines-in-the-treatment-of-spinal-cord-injury/2020-10-06T09:51:39-04:00https://respirerx.com/10-27-2020-respirerx-pharmaceuticals-inc-announces-appointment-of-dr-james-cook-and-dr-jeffrey-witkin-as-research-fellows/2020-10-27T20:24:20-04:00https://respirerx.com/11-12-2020-respirerx-november-2020-slide-deck/2020-11-12T13:58:34-05:00https://respirerx.com/respirerx-corporate-slide-deck-q4-2020/2020-12-17T21:11:39-05:00https://respirerx.com/1995-2/2021-01-05T18:40:58-05:00https://respirerx.com/1-8-2021-respirerx-pharmaceuticals-inc-to-participate-in-upcoming-january-virtual-investor-conferences/2021-01-08T09:27:21-05:00https://respirerx.com/respirerx-pharmaceuticals-inc-announces-10-to-1-reverse-stock-split/2021-02-08T14:44:33-05:00https://respirerx.com/2-8-2021-corrected-headline-respirerx-pharmaceuticals-up-listed-to-otcqb-and-ticker-returns-to-rspi/2021-02-08T20:56:39-05:00https://respirerx.com/2021-2/2021-04-22T12:59:10-04:00https://respirerx.com/5-12-2021-respirerx-pharmaceuticals-inc-announces-new-data-regarding-the-use-of-ampakines-as-potential-treatments-for-spinal-cord-injury/2021-05-12T15:44:04-04:00https://respirerx.com/2045-2/2021-06-08T19:20:11-04:00https://respirerx.com/11-4-2021-respirerx-pharmaceuticals-inc-announces-video-interview-of-cfo/2021-11-04T11:02:13-04:00https://respirerx.com/watch-respirerx-cfo-jeff-margolis-discusses-clinical-pipeline-with-proactive-investors/2021-11-04T11:18:40-04:00https://respirerx.com/2277-2/2021-11-22T16:09:05-05:00https://respirerx.com/11-29-2021-respirerx-pharmaceuticals-inc-announces-publication-of-preclinical-results-supporting-the-use-of-ampakines-in-the-treatment-of-human-spinal-cord-injury/2021-11-29T10:07:01-05:00https://respirerx.com/11-30-2021-respirerx-pharmaceuticals-inc-announces-publication-of-book-chapter-describing-novel-analgesic-properties-of-krm-ii-81/2021-11-30T10:27:31-05:00https://respirerx.com/12-6-2021-respirerx-pharmaceuticals-inc-announces-publication-of-review-article-describing-advances-in-the-discovery-development-and-commercialization-of-gabakines-including-krm-ii-81/2021-12-06T10:22:06-05:00https://respirerx.com/12-14-2021-respirerx-pharmaceuticals-inc-to-present-at-upcoming-virtual-life-sciences-investor-conference-and-biotech-showcase/2021-12-14T09:48:19-05:00https://respirerx.com/1-24-2022-respirerx-pharmaceuticals-inc-announces-publication-of-a-manuscript-describing-its-newest-neuromodulator-for-pharmacoresistant-epilepsy-and-chronic-pain/2022-01-24T10:48:55-05:00https://respirerx.com/3-7-2022-letter-to-stockholders-and-other-stakeholders-a-brief-summary-of-our-progress-during-past-twelve-months-and-a-peek-looking-forward/2022-03-07T10:40:55-05:00https://respirerx.com/3-7-22-respirerx-pharmaceuticals-ceo-announces-internal-restructuring-plans-further-clinical-trials-in-2022/2022-03-10T18:03:13-05:00https://respirerx.com/a-hrefhttps-www-proactiveinvestors-com-companies-news-976454-respirerx-pharmaceuticals-is-developing-innovative-and-revolutionary-treatments-to-combat-neuronal-signaling-disorders-976454-html3/2022-03-10T18:07:17-05:00https://respirerx.com/3-16-22-respirerx-pharmaceuticals-inc-announces-discovery-of-a-new-gabakine-neuromodulator-that-protects-against-seizures-and-lethality/2022-03-16T10:40:47-04:00https://respirerx.com/3-17-2022-proactive-investors-respirerx-pharmaceuticals-notes-publication-of-paper-on-newest-gabakine-analog-which-protects-against-seizures-and-lethality/2022-03-17T19:37:29-04:00https://respirerx.com/3-23-2022-respirerx-pharmaceuticals-inc-announces-patent-filings-claiming-novel-lipid-based-formulations-for-insoluble-compounds-including-cannabinoids-such-as-dronabinol/2022-03-23T11:38:24-04:00https://respirerx.com/a-hrefhttp-respirerx-com-wp-content-uploads-2022-03-respirerx-proactivemediacoverage03232022-pdf3-24-2022-media-coverage-respirerx-pharmaceuticals-files-provisional-patent-that-may/2022-03-24T16:08:25-04:00https://respirerx.com/3-29-22-watch-respirerx-interim-ceo-discusses-provisional-application-for-a-novel-lipid-based-formulation-technology-lft/2022-03-29T16:27:29-04:00https://respirerx.com/5-16-22-respirerx-pharmaceuticals-inc-announces-the-publication-of-a-review-article-highlighting-the-potential-use-of-gabakine-neuromodulators-for-the-treatment-of-tinnitus/2022-05-16T09:17:24-04:00https://respirerx.com/5-17-22-respirerx-pharmaceuticals-inc-announces-respirerx-presentation-at-2022-gri-virtual-conference-presented-by-curegrin-and-grin-therapeutics/2022-05-17T09:37:24-04:00https://respirerx.com/05-24-22-respirerx-pharmaceuticals-inc-announces-that-dr-lippa-is-an-invited-speaker-at-the-5th-international-cannabinoid-derived-pharmaceuticals-summit/2022-11-08T18:26:13-05:00https://respirerx.com/05-24-22-respirerx-pharmaceuticals-inc-announces-that-sleep-review-has-discussed-the-respirerx-dronabinol-obstructive-sleep-apnea-osa-program-in-its-june-13-2022-edition/2022-11-08T18:25:09-05:00https://respirerx.com/09-07-22-resolutionrx-slide-deck-presented-at-2022-cannabinoid-summit/2022-09-25T15:40:20-04:00https://respirerx.com/11-07-2022-respirerx-pharmaceuticals-inc-announces-that-dr-arnold-lippa-is-an-invited-speaker-at-the-5th-meridian-drug-discovery-summit/2022-11-08T18:23:46-05:00https://respirerx.com/11-10-22-respirerx-pharmaceuticals-inc-announces-that-jeff-margolis-the-companys-cfo-is-presenting-at-the-investor-summit-q4/2022-11-10T10:01:48-05:00https://respirerx.com/11-17-22-respirerx-pharmaceuticals-inc-announces-entry-into-letter-of-intent-with-australian-headquartered-cro-for-dronabinol-development-for-sleep-apnea/2022-11-17T10:12:06-05:00https://respirerx.com/post/2022-12-05T09:59:16-05:00https://respirerx.com/wp-content/uploads/2023/01/RespireRx-Press-Release-011223.pdf#new_tab2023-01-23T12:05:48-05:00https://respirerx.com/wp-content/uploads/2023/01/RespireRx-PR-Jan-23-23.pdf#new_tab2023-01-23T12:05:20-05:00https://respirerx.com/wp-content/uploads/2023/02/RSPI-ResolutionRx-Press-Release-02012023.pdf#new_tab2023-02-01T09:51:58-05:00https://respirerx.com/wp-content/uploads/2023/03/RespireRx-ResolutionRx-Press-Release-03012023.pdf#new_tab2023-03-01T09:54:01-05:00https://respirerx.com/wp-content/uploads/2023/03/RespireRx-Press-Release-03282023.pdf#new_tab2023-03-29T09:36:29-04:00https://respirerx.com/wp-content/uploads/2023/04/RespireRx-Press-Release-04032023.pdf2023-04-03T10:57:43-04:00https://respirerx.com/wp-content/uploads/2023/04/RespireRx-Press-Release-04052023.pdf#new_tab2023-04-05T10:10:17-04:00https://respirerx.com/wp-content/uploads/2023/05/RSPI-Press-Release-052422023.pdf#new_tab2023-05-24T09:40:46-04:00https://respirerx.com/wp-content/uploads/2023/08/RSPI-Press-Release-August-9-2023.pdf#new_tab2023-08-09T09:22:52-04:00https://respirerx.com/wp-content/uploads/2023/10/RespireRx-ResolutionRx-Press-Release-10-12-23.pdf#new_tab2023-10-12T17:25:20-04:00https://respirerx.com/wp-content/uploads/2023/12/RespireRx-Press-Release-Dec-11-23.pdf#new_tab2023-12-11T09:47:52-05:00https://respirerx.com/wp-content/uploads/2024/01/RespireRx-January-4-2024-1.pdf#new_tab2024-01-04T11:42:17-05:00https://respirerx.com/wp-content/uploads/2024/01/RespireRx-Press-Release-January-22-2024.pdf#new_tab2024-01-22T10:34:49-05:00https://respirerx.com/wp-content/uploads/2024/02/RespireRx-Press-Release-February-13-2024.pdf#new_tab2024-02-13T13:38:43-05:00https://respirerx.com/wp-content/uploads/2024/03/RespireRx-SCI-Bladder-paper-final-approved-for-distribution.pdf2024-03-26T11:14:15-04:00https://respirerx.com/wp-content/uploads/2024/05/RespireRx-DOD-Press-Release-05292024.pdf#new_tab2024-05-29T09:40:03-04:00https://respirerx.com/wp-content/uploads/2025/11/Press-Release-SEC-dated-11182025-authorized-for-distribution-and-posting-to-LinkedIn.pdf2025-11-19T13:44:40-05:00https://respirerx.com/wp-content/uploads/2025/11/Press-Release-re-Castle-Placement-Offering-dated-11182025-authorized-to-distribute-and-posting-to-linkedin.pdf2025-11-19T13:40:31-05:00https://respirerx.com/wp-content/uploads/2025/11/Press-Release-GABAkines-Grant-and-Amended-License-Agmt-dated-11192025-clean-received-from-printer-at-5pm-11182025-and-approved-for-distribution.pdf2025-11-19T13:37:29-05:00https://respirerx.com/wp-content/uploads/2025/11/RespireRx-Press-Release-02102025-Letter-to-Shareholders-clipped-from-Form-8-K.pdf2025-11-19T14:02:36-05:00https://respirerx.com/wp-content/uploads/2025/11/Press-Release-Letter-to-shareholders-and-stakeholder-11202025-APPROVED-for-distribution-FINAL.pdf2025-11-20T17:19:35-05:00